“Growth is expensive”: Inside Fingerpaint’s decision to take on an equity partner
With revenue up 60% in 2020, the 12-year-old firm is eyeing acquisitions and membership in the $100 million club.
With revenue up 60% in 2020, the 12-year-old firm is eyeing acquisitions and membership in the $100 million club.
Dr. Christiana Bardon is managing director of the Oncology Impact Fund for MPM Capital.